Subtopic Deep Dive
Neuroblastoma Risk Classification Systems
Research Guide
What is Neuroblastoma Risk Classification Systems?
Neuroblastoma Risk Classification Systems are standardized frameworks like INSS and INRGSS that integrate clinical stage, age, histology, and molecular markers to stratify patients into low, intermediate, or high-risk groups for prognosis and treatment guidance.
The International Neuroblastoma Staging System (INSS) was revised in 1993 by Brodeur et al. (2299 citations) to clarify diagnosis, staging, and response criteria. The INRG Classification System, introduced by Cohn et al. (2008, 1832 citations), uses image-defined risk factors and biology for pretreatment risk assignment. These systems enable global comparison of clinical trials.
Why It Matters
Risk classification determines treatment intensity, reducing overtreatment in low-risk cases and intensifying therapy for high-risk neuroblastoma, which comprises 50% of cases with poor survival (Cohn et al., 2008). Matthay et al. (1999, 1892 citations) showed high-risk patients benefit from myeloablative therapy and 13-cis-retinoic acid, improving event-free survival. Accurate stratification minimizes long-term morbidity from chemotherapy and radiotherapy in children (Maris et al., 2007).
Key Research Challenges
Standardizing Global Risk Assignment
Variations in INSS and INRGSS application across countries hinder trial comparisons (Cohn et al., 2008). Brodeur et al. (1993) addressed INSS revisions due to inconsistent staging. Uniform criteria remain needed for diverse cohorts.
Integrating Molecular Markers
Incorporating ALK mutations and genomic alterations into risk systems requires validation (Mossé et al., 2008). Brodeur (2003) highlighted biological enigmas like MYCN amplification. Large cohort studies are essential for prognostic accuracy.
Validating Pretreatment Risk Factors
INRGSS relies on image-defined risk factors before surgery, but validation in real-world settings is limited (Cohn et al., 2008). Histology and age integration needs refinement per Matthay et al. (2016). Response prediction challenges persist.
Essential Papers
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
G M Brodeur, Jon Pritchard, Frank Berthold et al. · 1993 · Journal of Clinical Oncology · 2.3K citations
PURPOSE AND METHODS: Based on preliminary experience, there was a need for modifications and clarifications in the International Neuroblastoma Staging System (INSS) and International Neuroblastoma ...
Neuroblastoma: biological insights into a clinical enigma
Garrett M. Brodeur · 2003 · Nature reviews. Cancer · 2.2K citations
Neuroblastoma
John M. Maris, Michael D. Hogarty, Rochelle Bagatell et al. · 2007 · The Lancet · 2.0K citations
Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-<i>cis</i>-Retinoic Acid
Katherine K. Matthay, Judith G. Villablanca, Robert C. Seeger et al. · 1999 · New England Journal of Medicine · 1.9K citations
Treatment with myeloablative therapy and autologous bone marrow transplantation improved event-free survival among children with high-risk neuroblastoma. In addition, treatment with 13-cis-retinoic...
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Susan L. Cohn, Andrew D.J. Pearson, Wendy B. London et al. · 2008 · Journal of Clinical Oncology · 1.8K citations
Purpose Because current approaches to risk classification and treatment stratification for children with neuroblastoma (NB) vary greatly throughout the world, it is difficult to directly compare ri...
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · 2010 · New England Journal of Medicine · 1.7K citations
Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the...
The landscape of genomic alterations across childhood cancers
Susanne Gröbner, Barbara C. Worst, Joachim Weischenfeldt et al. · 2018 · Nature · 1.5K citations
Reading Guide
Foundational Papers
Read Brodeur et al. (1993) first for INSS revisions establishing staging basics (2299 citations), then Cohn et al. (2008) for INRGSS introducing pretreatment risk (1832 citations).
Recent Advances
Study Matthay et al. (2016) for updated primers on risk-integrated treatments; Gröbner et al. (2018) for genomic alterations in classification.
Core Methods
Core techniques: INSS surgical staging (Brodeur 1993), INRG image-defined risk factors (Cohn 2008), MYCN/ALK molecular scoring (Brodeur 2003; Mossé 2008).
How PapersFlow Helps You Research Neuroblastoma Risk Classification Systems
Discover & Search
Research Agent uses searchPapers and citationGraph on 'INRG classification system' to map 1832 citations from Cohn et al. (2008), revealing connections to Brodeur (1993) INSS revisions. exaSearch uncovers cohort validation studies; findSimilarPapers links to Matthay et al. (1999) high-risk outcomes.
Analyze & Verify
Analysis Agent applies readPaperContent to extract INRGSS criteria from Cohn et al. (2008), then verifyResponse with CoVe checks risk stratification claims against Brodeur (1993). runPythonAnalysis computes survival statistics from cohort data using pandas; GRADE grading scores evidence strength for molecular integration.
Synthesize & Write
Synthesis Agent detects gaps in ALK marker validation (Mossé et al., 2008) and flags contradictions between INSS and INRGSS. Writing Agent uses latexEditText for risk table edits, latexSyncCitations for Brodeur references, and latexCompile for report generation; exportMermaid visualizes classification flowcharts.
Use Cases
"Extract survival data from high-risk neuroblastoma cohorts and plot Kaplan-Meier curves."
Research Agent → searchPapers 'high-risk neuroblastoma survival' → Analysis Agent → readPaperContent (Matthay 1999) → runPythonAnalysis (pandas survival analysis, matplotlib plot) → matplotlib figure of event-free survival.
"Draft a review section comparing INSS vs INRGSS with citations and flowchart."
Research Agent → citationGraph 'Cohn 2008 INRG' → Synthesis Agent → gap detection → Writing Agent → latexEditText (comparison table) → latexSyncCitations (Brodeur 1993) → latexCompile → exportMermaid (risk stratification diagram).
"Find code for neuroblastoma genomic risk models from papers."
Research Agent → searchPapers 'neuroblastoma risk genomic' → Code Discovery → paperExtractUrls (Gröbner 2018) → paperFindGithubRepo → githubRepoInspect → R script for ALK/MYCN risk scoring.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'INRGSS validation cohorts', structures report with GRADE-scored evidence from Cohn (2008) and Brodeur (1993). DeepScan's 7-step chain verifies molecular risk factors: readPaperContent → CoVe → runPythonAnalysis on survival data. Theorizer generates hypotheses on next INRG updates from gaps in Mossé (2008) ALK data.
Frequently Asked Questions
What is the definition of INRG Classification System?
INRGSS stratifies neuroblastoma risk pretreatment using image-defined risk factors, age, histology, and biology like MYCN status (Cohn et al., 2008).
What are key methods in neuroblastoma risk classification?
INSS uses postsurgical staging; INRGSS employs presurgical imaging and molecular markers like ALK mutations (Brodeur et al., 1993; Cohn et al., 2008).
What are seminal papers on risk systems?
Brodeur et al. (1993, 2299 citations) revised INSS; Cohn et al. (2008, 1832 citations) defined INRGSS.
What open problems exist in risk classification?
Challenges include standardizing molecular integration like ALK (Mossé et al., 2008) and validating INRGSS in diverse global cohorts.
Research Neuroblastoma Research and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neuroblastoma Risk Classification Systems with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers